Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Published

Journal Article

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

Full Text

Duke Authors

Cited Authors

  • Tempero, MA; Malafa, MP; Al-Hawary, M; Asbun, H; Bain, A; Behrman, SW; Benson, AB; Binder, E; Cardin, DB; Cha, C; Chiorean, EG; Chung, V; Czito, B; Dillhoff, M; Dotan, E; Ferrone, CR; Hardacre, J; Hawkins, WG; Herman, J; Ko, AH; Komanduri, S; Koong, A; LoConte, N; Lowy, AM; Moravek, C; Nakakura, EK; O'Reilly, EM; Obando, J; Reddy, S; Scaife, C; Thayer, S; Weekes, CD; Wolff, RA; Wolpin, BM; Burns, J; Darlow, S

Published Date

  • August 2017

Published In

Volume / Issue

  • 15 / 8

Start / End Page

  • 1028 - 1061

PubMed ID

  • 28784865

Pubmed Central ID

  • 28784865

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

International Standard Serial Number (ISSN)

  • 1540-1405

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2017.0131

Language

  • eng